Skip to main content

Advertisement

SpringerLink
Log in

Sjögren’s syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review

  • Case Based Review
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a potentially lethal multisystem disorder which could be caused by autoimmune diseases. However, the concomitant occurrence of TTP and Sjögren’s syndrome (SS) is an extremely uncommon scenario, especially in male patients. A 56-year-old Chinese male was admitted for the appearance of diffuse ecchymosis. Then he gradually developed transient slurred speech, progressive confusion, agitation, extremity weakness, and fever. Laboratory investigations suggested anemia, thrombocytopenia, significantly increased lactic dehydrogenase, schistocytes in peripheral blood smear, and a disintegrin-like metalloproteinase with thrombospondin motif type 1 member 13 (ADAMTS13) activity deficiency with high inhibitor titers. TTP was thus diagnosed. The patient also had positive anti-nuclear antibody, anti-SSA, and anti-SSB; however, anti-double stranded DNA (dsDNA) was negative. These drove us to perform ocular and dental sicca evaluation and the finial diagnosis was TTP secondary to SS. Plasma exchange and corticosteroid therapy were effective to control TTP. Cyclophosphamide was subsequently added when the platelet count was stable. The total duration of corticosteroid and cyclophosphamide was 8 and 6 months, respectively. The patient recovered without relapse at 1-year follow-up. To our knowledge, this was the first case of SS initially presented as TTP in a male patient. The case also elucidated the importance of autoantibody screen in the workup of TTP and the benefits of adjunctive immunosuppressive therapy in relapse prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Abe H, Tsuboi N, Yukawa S, Tsuji S, Hayashi H, Yukawa N, Takanashi H, Tahara K, Tonozuka N, Hayashi T (2004) Thrombotic thrombocytopenic purpura complicating Sjogren’s syndrome with crescentic glomerulonephritis and membranous nephritis. Mod Rheumatol 14(2):174–178. https://doi.org/10.1007/s10165-004-0287-4

    Article  PubMed  Google Scholar 

  2. Abu-Hishmeh M, Sattar A, Zarlasht F, Ramadan M, Abdel-Rahman A, Hinson S, Hwang C (2016) Systemic lupus erythematosus presenting as refractory thrombotic thrombocytopenic purpura: a diagnostic and management challenge. A case report and concise review of the literature. Am J Case Rep 17:782–787. 10.12659/AJCR.898955

    Article  PubMed  PubMed Central  Google Scholar 

  3. Allan DS, Kovacs MJ, Clark WF (2001) Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy. Haematologica 86(8):844–850

    CAS  PubMed  Google Scholar 

  4. Barone F, Colafrancesco S (2016) Sjogren’s syndrome: from pathogenesis to novel therapeutic targets. Clin Exp Rheumatol 34(4 Suppl 98):58–62

    PubMed  Google Scholar 

  5. Bartoloni E, Alunno A, Bistoni O, Caterbi S, Luccioli F, Santoboni G, Mirabelli G, Cannarile F, Gerli R (2015) Characterization of circulating endothelial microparticles and endothelial progenitor cells in primary Sjogren’s syndrome: new markers of chronic endothelial damage? Rheumatology (Oxford) 54(3):536–544. https://doi.org/10.1093/rheumatology/keu320

    Article  CAS  Google Scholar 

  6. Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pene F, Mira JP, Galicier L, Guidet B, Baudel JL, Subra JF, Tanguy-Schmidt A, Pourrat J, Azoulay E, Veyradier A, Coppo P (2012) Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion 52(11):2436–2444. https://doi.org/10.1111/j.1537-2995.2012.03578.x

    Article  PubMed  Google Scholar 

  7. Brandt JE, Priori R, Valesini G, Fairweather D (2015) Sex differences in Sjogren’s syndrome: a comprehensive review of immune mechanisms. Biol Sex Differ 6(1):19. https://doi.org/10.1186/s13293-015-0037-7

    Article  PubMed  PubMed Central  Google Scholar 

  8. Brito-Zeron P, Ramos-Casals M (2014) Advances in the understanding and treatment of systemic complications in Sjogren’s syndrome. Curr Opin Rheumatol 26(5):520–527. https://doi.org/10.1097/bor.0000000000000096

    Article  PubMed  Google Scholar 

  9. Campbell GN, Gallo JH (1998) Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjogren’s syndrome. Aust NZ J Med 28(2):214. https://doi.org/10.1111/j.1445-5994.1998.tb02974.x

    Article  CAS  Google Scholar 

  10. Chauhan AK, Goerge T, Schneider SW, Wagner DD (2007) Formation of platelet strings and microthrombi in the presence of ADAMTS-13 inhibitor does not require P-selectin or beta3 integrin. J Thromb Haemost 5(3):583–589. https://doi.org/10.1111/j.1538-7836.2006.02361.x

    Article  CAS  PubMed  Google Scholar 

  11. Coppo P (2017) Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Transfus Apher Sci 56(1):52–56. https://doi.org/10.1016/j.transci.2016.12.019

    Article  PubMed  Google Scholar 

  12. Coppo P, Veyradier A (2012) Current management and therapeutical perspectives in thrombotic thrombocytopenic purpura. Presse Med 41(3):e163–e176. https://doi.org/10.1016/j.lpm.2011.10.024

    Article  PubMed  Google Scholar 

  13. George JN (2012) Corticosteroids and rituximab as adjunctive treatments for thrombotic thrombocytopenic purpura. Am J Hematol 87(Suppl 1):S88–S91. https://doi.org/10.1002/ajh.23126

    Article  CAS  PubMed  Google Scholar 

  14. Guzicka-Kazimierczak R, Kazimierczak A, Clark J (2015) Promising results from cyclophosphamide based immunosuppression therapy of thrombotic thrombocytopenic purpura. Pomeranian J Life Sci 61(1):34–40

    Article  PubMed  Google Scholar 

  15. Hertzberg MS, Koutts J (1997) Oral cyclophosphamide for refractory or relapsing thrombotic thrombocytopenic purpura (TTP). Aust NZ J Med 27(4):439. https://doi.org/10.1111/j.1445-5994.1997.tb02204.x

    Article  CAS  Google Scholar 

  16. Jonsson R, Theander E, Sjostrom B, Brokstad K, Henriksson G (2013) Autoantibodies present before symptom onset in primary Sjogren syndrome. JAMA 310(17):1854–1855. https://doi.org/10.1001/jama.2013.278448

    Article  CAS  PubMed  Google Scholar 

  17. Knobl P (2014) Inherited and acquired thrombotic thrombocytopenic purpura (TTP) in adults. Semin Thromb Hemost 40(04):493–502. https://doi.org/10.1055/s-0034-1376883

    Article  PubMed  Google Scholar 

  18. Koga T, Yamasaki S, Nakamura H, Kawakami A, Furusu A, Taguchi T, Eguchi K (2013) Renal thrombotic microangiopathies/thrombotic thrombocytopenic purpura in a patient with primary Sjogren’s syndrome complicated with IgM monoclonal gammopathy of undetermined significance. Rheumatol Int 33(1):227–230. https://doi.org/10.1007/s00296-010-1569-0

    Article  PubMed  Google Scholar 

  19. Lim W, Vesely SK, George JN (2015) The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood 125(10):1526–1531. https://doi.org/10.1182/blood-2014-10-559211

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lin TY, Chang CC, Chang CC, Yuan JY, Chen HH (2012) Cyclophosphamide-rescued plasmapheresis-unresponsive secondary thrombotic thrombocytopenic purpura caused by Sjogren’s syndrome. Arch Med Sci 8(5):934–938. https://doi.org/10.5114/aoms.2012.30788

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provot F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, Veyradier A (2016) Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol 3(5):e237–e245. https://doi.org/10.1016/s2352-3026(16)30018-7

    Article  PubMed  Google Scholar 

  22. Murrin RJ, Murray JA (2006) Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev 20(1):51–60. https://doi.org/10.1016/j.blre.2005.02.001

    Article  CAS  PubMed  Google Scholar 

  23. Noda M, Kitagawa M, Tomoda F, Iida H (1990) Thrombotic thrombocytopenic purpura as a complicating factor in a case of polymyositis and Sjogren’s syndrome. Am J Clin Pathol 94(2):217–221. https://doi.org/10.1093/ajcp/94.2.217

    Article  CAS  PubMed  Google Scholar 

  24. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2016) Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura. Blood 128(17):2175–2178. https://doi.org/10.1182/blood-2016-06-724161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Page EE, Kremer Hovinga JA, Terrell DR, Vesely SK, George JN (2016) Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. Blood 127(24):3092–3094. https://doi.org/10.1182/blood-2016-03-70382

    Article  CAS  PubMed  Google Scholar 

  26. Porola P, Laine M, Virkki L, Poduval P, Konttinen YT (2007) The influence of sex steroids on Sjogren’s syndrome. Ann N Y Acad Sci 1108(1):426–432. https://doi.org/10.1196/annals.1422.045

    Article  CAS  PubMed  Google Scholar 

  27. Porola P, Laine M, Virtanen I, Pollanen R, Przybyla BD, Konttinen YT (2010) Androgens and integrins in salivary glands in Sjogren’s syndrome. J Rheumatol 37(6):1181–1187. https://doi.org/10.3899/jrheum.091354

    Article  CAS  PubMed  Google Scholar 

  28. Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, Baudel JL, Provot F, Pene F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, Chauveau D, Veyradier A, Halimi JM, Hamidou M, Coppo P (2015) Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore) 94(42):e1598. https://doi.org/10.1097/md.0000000000001598

    Article  CAS  Google Scholar 

  29. Sadler JE, Moake JL, Miyata T, George JN (2004) Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004(1):407–423. https://doi.org/10.1182/asheducation-2004.1.407

    Google Scholar 

  30. Sandhya P, Jeyaseelan L, Scofield RH, Danda D (2015) Clinical characteristics and outcome of primary Sjogren’s syndrome: a large Asian Indian cohort. Open Rheumatol J 9(1):36–45. https://doi.org/10.2174/1874312901409010036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Sayani FA, Abrams CS (2015) How I treat refractory thrombotic thrombocytopenic purpura. Blood 125(25):3860–3867. https://doi.org/10.1182/blood-2014-11-551580

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Schattner A, Friedman J, Klepfish A (2002) Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren’s syndrome. Clin Rheumatol 21(1):57–59. https://doi.org/10.1007/s100670200013

    Article  CAS  PubMed  Google Scholar 

  33. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lammle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H (2017) Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 15(2):312–322. https://doi.org/10.1111/jth.13571

    Article  CAS  PubMed  Google Scholar 

  34. Selva O'Callaghan A, Bosch Gil JA, Solans Laque R, Segura Garcia A, Armadans Gil L, Mijares Boeckh-Behrens T, Vilardell Tarres M (2001) Primary Sjogren’s syndrome: clinical and immunological characteristics of 114 patients. Med Clin (Barc) 116(19):721–725

    Article  Google Scholar 

  35. Shenkman B, Einav Y (2014) Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification. Autoimmun Rev 13(4-5):584–586. https://doi.org/10.1016/j.autrev.2014.01.004

    Article  CAS  PubMed  Google Scholar 

  36. Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM, Rasmussen A, Scofield H, Vitali C, Bowman SJ, Mariette X (2017) 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 76(1):9–16. https://doi.org/10.1136/annrheumdis-2016-210571

    Article  PubMed  Google Scholar 

  37. Steinberg AD, Green WT Jr, Talal N (1971) Thrombotic thrombocytopenic purpura complicating Sjogren’s syndrome. JAMA 215(5):757–761. https://doi.org/10.1001/jama.1971.03180180033007

    Article  CAS  PubMed  Google Scholar 

  38. Toumeh A, Josh N, Narwal R, Assaly R (2014) Refractory thrombotic thrombocytopenic purpura associated with primary Sjogren syndrome treated with rituximab: a case report. Am J Ther 21(2):e56–e60. https://doi.org/10.1097/MJT.0b013e3182459aa0

    Article  PubMed  Google Scholar 

  39. Verbeke L, Delforge M, Dierickx D (2010) Current insight into thrombotic thrombocytopenic purpura. Blood Coagul Fibrinolysis 21(1):3–10. https://doi.org/10.1097/MBC.0b013e32833335eb

    Article  PubMed  Google Scholar 

  40. Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, HM W (2015) Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion 55(1):18–24. https://doi.org/10.1111/trf.12762

    Article  CAS  PubMed  Google Scholar 

  41. Yamashita H, Takahashi Y, Kaneko H, Kano T, Mimori A (2013) Thrombotic thrombocytopenic purpura with an autoantibody to ADAMTS13 complicating Sjogren’s syndrome: two cases and a literature review. Mod Rheumatol 23(2):365–373. https://doi.org/10.1007/s10165-012-0644-7

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongdansantiao Street, Dongcheng District, Beijing, 100730, China

    Xiaohan Xu

  2. Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongdansantiao Street, Dongcheng District, Beijing, 100730, China

    Tienan Zhu & Lu Zhang

  3. Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Dongdansantiao Street, Dongcheng District, Beijing, 100730, China

    Di Wu

Authors
  1. Xiaohan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tienan Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Di Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lu Zhang.

Ethics declarations

Consent

A written informed consent was signed by the patient concerning publication of this case report. A copy of this consent is available for editors of this journal.

Disclosures

None.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, X., Zhu, T., Wu, D. et al. Sjögren’s syndrome initially presented as thrombotic thrombocytopenic purpura in a male patient: a case report and literature review. Clin Rheumatol 37, 1421–1426 (2018). https://doi.org/10.1007/s10067-017-3912-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-017-3912-2

Keywords

Search

Navigation